# DESCRIPTION

## FIELD OF THE INVENTION

- introduce methods and compositions for treating kidney injury

## BACKGROUND OF THE INVENTION

- describe iodinated radiocontrast media
- discuss ionic and nonionic radiocontrast media
- describe risk factors for contrast-induced nephropathy
- discuss limitations of current treatments
- introduce antioxidants as adjunctive cytoprotective agents
- discuss vasodilators and vasoconstrictor antagonists
- describe intravenous administration of isotonic fluids
- introduce PACAP and its properties
- discuss PACAP receptors and signal transduction pathways
- describe PACAP's effects on catecholamine secretion and immune response
- discuss PACAP's neuroprotective effects
- describe drawbacks of using peptides for neuroprotection
- discuss PACAP's effects on kidney injury
- introduce PACAP-like peptides and their effects on hematopoietic cells
- discuss human clinical trials with PACAP

## SUMMARY OF THE INVENTION

- introduce PACAP38 and PACAP analogs
- describe protection of organs against injury
- detail administration methods
- specify effective concentration range
- describe peak effectiveness
- outline combination therapy
- identify risk factors for injury
- describe biomarkers for injury assessment
- detail therapy assessment methods
- summarize therapy benefits

## SEQUENCES

- introduce human sequences
- describe modifications of human sequences
- detail SEQ ID NO:1-3
- describe SEQ ID NO:4-70
- outline PACAP38 modifications
- outline PACAP27 modifications
- outline VIP modifications
- describe non-human PACAP38 sequences
- summarize sequence listing

## DEFINITIONS

- define amino acid abbreviations
- define "about"
- define "administration"
- define "analog"
- define "derivative"
- define "fragment"
- define "hematopoietic"
- define "in combination with"
- define "nervous system"
- define "PACAP"
- define "PACAP/VIP receptor agonist"
- define "PACAP-like compound"
- define "peptidomimetic"
- define "percent identity" and "percent similarity"
- define "subject" or "mammal"

## DETAILED DESCRIPTION OF THE INVENTION

- describe damage reduction by PACAP38 and analogs

### Identification of Pacap-Like Compounds

- introduce PACAP-like compounds
- describe assays for PACAP-like compounds
- determine intrinsic activity of PACAP-like compounds

### Patient Population

- identify patient population at risk
- describe diagnosis and monitoring of patient population

### Other Therapeutic/Prophylactic Agents

- introduce other cytoprotective agents and vasodilators

### Synthesis of PACAP38, PACAP27, VIP, and Related Analogs

- describe synthesis of PACAP38, PACAP27, VIP, and related analogs
- detail peptide synthesis procedures
- describe purification and characterization of synthesized compounds

### Mouse Model of Contrast-Induced Nephropathy

- introduce homozygous eNOS-deficient mouse model

### Therapeutic Testing and Monitoring

- describe in vitro and in vivo testing of therapeutic protocols
- introduce biomarkers for monitoring organ injury
- describe imaging and functional tests for monitoring organ injury

### Pharmaceutical Composition

- define pharmaceutical composition
- describe bulk drug compositions
- describe parenteral pharmaceutical compositions
- specify prophylactically or therapeutically effective amount
- define pharmaceutically acceptable
- describe pharmaceutical carriers
- list pharmaceutical excipients
- describe composition forms
- describe delivery methods
- specify routes of administration
- describe controlled release formulations
- describe sustained release formulations
- describe administration methods
- describe formulation presentation

## EXAMPLES

- illustrate uses of the present invention

### Example 1

- demonstrate reduction of Urografin-induced renal epithelial cell toxicity
- show cytoprotective effect of PACAP38 against Urografin-induced nephrotoxicity

### Example 2

- demonstrate reduction of iohexol-induced renal epithelial cell toxicity

### Example 3

- demonstrate reduction of Urografin-induced inflammatory responses in the kidney

### Example 4

- demonstrate reduction of Urografin-induced fibrotic responses in the kidney

### Example 5

- demonstrate reduction of Urografin-induced oxidative stress in the kidney

## EQUIVALENTS

- acknowledge equivalents to specific embodiments of the present invention

